The Board of Directors of Cell Impact AB ("Cell Impact" or the "Company") resolved on 29 June 2026, subject to subsequent approval by an Extraordinary General Meeting, to carry out a rights issue of units of approximately SEK 53.6 million with a subscription period from and including 6 August 2026 up to and including 20 August 2026 (the "Rights Issue"), which was subsequently approved by an Extraordinary General Meeting of the Company on 31 July 2026. In connection with the ongoing subscription period in the Rights Issue, Cell Impact's CEO, Daniel Vallin, has conducted a CEO interview with Mangold Insight, which has been published and is available on the Company's and Mangold Insight's respective websites (https://investor.cellimpact.com/en/investor-relations/issues/rights-issue-2026-2 and https://mangold.se/mangold-insight/bolag/cell-impact/).

In an interview with Mangold Insight, Cell Impact's CEO Daniel Vallin describes the Company's patented technology Cell Impact Forming™ and its competitive advantages in the manufacture of flow plates for fuel cells and electrolysers. According to Vallin, the technology already enables a cost level that is about 50 percent lower than that of competing manufacturers, while forming in a single stroke provides quality benefits.

Cell Impact has broadened its customer base to customers on three continents and works on projects in areas such as automotive, aviation, marine and stationary energy solutions. The projects normally have a lead time of three to five years, and according to Vallin, the Company has so far made progress in all start-up projects. A few projects are now approaching the transition from prototype to series production, which is expected to generate recurring revenue.

Vallin emphasises the breadth of customers, applications and business models as important for the Company's continued development. According to Vallin, the most important factor in achieving the Company's goals is that the projects continue to develop towards validation and series production. 

The Rights Issue in brief

• Those who were registered as shareholders in Cell Impact on the record date 4 August 2026 received one (1) unit right for each share in the Company. Three (3) unit rights entitle the holder to subscribe for one (1) unit in the Rights Issue. One (1) unit contains six (6) shares and two (2) warrants of series TO5, as well as two (2) warrants of series TO6.
• The subscription price per unit in the Rights Issue amounts to SEK 0.330, corresponding to SEK 0.055 per share as the warrants of series TO5 and TO6 are received free of charge.
• The Rights Issue may, if fully subscribed, provide Cell Impact with approximately SEK 53.6 million before issue costs.

• The subscription period for the Rights Issue runs from 6 August 2026 up to and including 20 August 2026.

• The Rights Issue is covered to approximately 3.4 percent by subscription commitments, corresponding to approximately SEK 1.8 million, and to approximately 71.6 percent by underwriting commitments, corresponding to approximately SEK 38.4 million. Thus, the Rights Issue is comprised to approximately 75 percent of subscription commitments and underwriting commitments, corresponding to approximately SEK 40.2 million.

Preliminary timetable for the Rights Issue

Advisors
Mangold Fondkommission AB is acting as financial advisor and Wåhlin Advokater AB is acting as legal advisor to Cell Impact in connection with the Rights Issue.

Important information
The publication, announcement or distribution of this press release may be subject to restrictions by law in certain jurisdictions and persons in the jurisdictions in which this press release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with applicable regulations in their respective jurisdictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Cell Impact in any jurisdiction, neither from Cell Impact nor from anyone else.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Nor will any information document pursuant to Annex IX of the Prospectus Regulation be prepared in connection with the Rights Issue. The Rights Issue is exempt from the prospectus requirement in accordance with Article 3(2) of the Prospectus Regulation and Chapter 2, Section 1 of the Swedish Act (2019:414) with supplementary provisions to the EU Prospectus Regulation, as the amount offered by the Company to the public over a twelve-month period is less than EUR 12 million.

This press release does not identify or purport to identify risks (direct or indirect) that may be attributable to an investment in the Company. The information in this press release is only to describe the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance should be made in relation to the information in this press release regarding its accuracy or completeness.

This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration, or without the application of an exemption from registration, under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration, an exemption from, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States, or to make a public offer of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable regulations or where such action is subject to legal restrictions or would require additional registration or other measures than what follows from Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

Forward-Looking Statements
This press release contains forward-looking statements that reflect the Company's intentions, beliefs or current expectations and objectives for the Company's future operations, financial condition, liquidity, earnings, prospects, expected growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "may" or, in each case, their negative, or similar, expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it cannot give any assurance that they will occur or prove to be accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or results could differ materially from those expressed in the forward-looking statements, which are the result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by such forward-looking statements. The Company does not warrant that the assumptions behind the forward-looking statements in this press release are free from errors and does not accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. The information, opinions and forward-looking statements contained in this press release relate only to the situation as of the date hereof and are subject to change without notice. The Company undertakes no obligation to review, update, confirm or publish any revisions to any forward-looking statements to reflect events that arise or circumstances that arise in relation to the content of this press release.

Information for distributors
In order to comply with the product governance requirements contained in: (a) Directive 2014/65/EU of the European Parliament and of the Council on markets in financial instruments, as amended, ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593, supplementing MiFID II; and (c) local implementing measures (collectively, the "MiFID II Product Governance Requirements"), and disclaiming any and all liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Offered Shares have been subject to a product approval process, which has determined that such securities are: (i) suitable for an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, as defined in MiFID II; and (ii) suitable for distribution through all distribution channels permitted under MiFID II (the "Target Market Assessment").

Notwithstanding the Target Market Assessment, distributors should note that: the price of the Company's shares may decrease and investors may lose all or part of their investment, that the Company's shares are not accompanied by any guarantee of return or capital protection, and that an investment in the Company's shares is only suitable for investors who are not in need of guaranteed returns or capital protection and who (alone or with the assistance of appropriate financial or other advisors) are capable of evaluating the benefits and risks of such investment and which has sufficient resources to bear the losses that such investment may result in. The target market assessment is without prejudice to other requirements regarding contractual, legal or regulatory sales restrictions due to the Rights Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute (a) an appropriateness or suitability assessment within the meaning of MiFID II or (b) a recommendation to any investor or group of investors to invest in, acquire, or take any other action in respect of the Company's shares.

Each distributor is responsible for conducting its own Target Market Assessment in respect of the Company's shares and for deciding on appropriate distribution channels.